Tandem Diabetes Care

Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006, and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Tandem Diabetes Care reports robust sales growth and strategic innovations

Tandem Diabetes Care's strong financial performance, innovative product portfolio, and global market expansion efforts position it for continued growth and competitiveness.
While facing short-term challenges like seasonal EBITDA fluctuations and acquisition-related headwinds, Tandem's strategic focus on new product launches and market awareness presents opportunities for long-term success.
The company's emphasis on technology advancements, clinical initiatives, and leadership continuity underscores its commitment to driving innovation and meeting customer needs in the insulin therapy market.
With a clear roadmap for 2023, including revenue projections, margin expectations, and product development plans, Tandem is poised to navigate challenges and capitalize on growth opportunities in the evolving healthcare landscape.

Tandem Diabetes Care reports strong Q1 performance amidst competitive challenges

Tandem Diabetes Care's Q1 2023 earnings call showcased strong performance driven by product success and customer loyalty, despite challenges in international revenue and competitive landscape noise.
The company's focus on innovation, cost management, and product enhancements positions it well for long-term growth and market expansion, with opportunities in Libre integration and upcoming product launches.
While facing short-term challenges in Q2 revenue and margins, Tandem Diabetes Care remains confident in achieving its objectives through prudent cost management and commitment to product excellence.

Tandem Diabetes Care exceeds Q2 targets, eyes sustainable growth

Tandem Diabetes Care (TNDM) showcased strong Q2 performance, with a focus on sustainable growth and profitability. While facing challenges like market uncertainties, the company is leveraging opportunities through new product launches and cost efficiencies for future growth.

Tandem Diabetes Care surpasses Q3 sales expectations amidst market challenges

Tandem Diabetes Care's Q3 performance exceeded expectations with strong sales and positive margins, despite challenges in OUS distribution.
The company's focus on innovation, product success, and market positioning sets the stage for future growth opportunities.
Navigating disruptions and seizing growth potential through new product launches and market expansion are key priorities for Tandem.
Overall, Tandem remains optimistic about its trajectory and is actively pursuing strategic opportunities for growth.

Tandem Diabetes Care reports strong sales growth and strategic focus

Tandem Diabetes Care's Q4 2023 Earnings Call highlighted strong sales performance, positive customer feedback, and strategic focus on new product launches and operational efficiencies.
While facing challenges from unique events and increasing competition, Tandem is leveraging opportunities in U.S. and international markets, focusing on growth and innovation.
The company's outlook for 2024 includes a robust sales guidance, expansion plans, and a strategic approach to address market challenges and capitalize on emerging opportunities.

Tandem Diabetes Care reports robust Q1 sales growth and international expansion

Tandem Diabetes Care's Q1 2024 earnings call highlighted strong sales growth, successful product launches, and innovation in AID systems, with a focus on maintaining pricing and expanding internationally.
Challenges include pricing strategies, monitoring Mobi's impact, and navigating competitive OUS markets, while opportunities lie in market expansion, health outcome studies validation, and improving access and affordability.
Overall, Tandem's performance reflects a strategic approach to growth through product innovation, market expansion, and a focus on enhancing access and affordability in the diabetes care market.

Tandem Diabetes Care (TNDM) posts strong Q2 results, raises 2024 guidance

Tandem Diabetes Care (TNDM) reported robust Q2 2024 performance with sales growth, improved gross margin, and raised sales guidance. The company's focus on new products and commercial excellence positions it well for future growth.

Tandem Diabetes Care achieves record sales and positive cash flow

Tandem Diabetes Care delivered a strong performance in Q3 2024, marked by record sales and positive free cash flow. The company's focus on innovation, market awareness, and customer retention are key strengths. While facing challenges in a competitive market, Tandem Diabetes Care is well-positioned to capitalize on growth opportunities in 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its products include Tandem Mobi System and t:slim X2 Insulin Pump. The company was founded by Paul M. DiPerna on January 27, 2006, and is headquartered in San Diego, CA.

Tandem Diabetes Care, Inc. (TNDM) CEO John Sheridan on Q3 2020 Results - Earnings Call Transcript

SAN DIEGO--(BUSINESS WIRE)---- $TNDM #ControlIQ--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2020 and updated its sales guidance for the year ending December 31, 2020. Third Quarter 2020 Highlights In comparing the third quarter of 2020 to the same period of 2019: Worldwide pump shipments increased 23 percent to 22,021 pumps from 17,839 pumps Sales increased 31 percent to $123.6 millio

Tandem Diabetes Care Announces Third Quarter 2020 Financial Results and Updated Full Year 2020 Sales Guidance

Block

This diabetes-focused healthcare company and financial services giant are ready to reward their shareholders.

2 Growth Stocks Poised to Triple Over the Next Decade

SAN DIEGO--(BUSINESS WIRE)---- $TNDM--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2020 results after the financial markets close on Thursday, November 5, 2020. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its third quarter 2020 financial and operating results. Conference Call/Webcast Details: Date: November 5, 2020 Tim

Tandem Diabetes Care to Announce Third Quarter 2020 Financial Results on November 5, 2020

Abbott Labs

Vertex Pharmaceuticals

These three stocks are among the few winners to emerge from the coronavirus stock market.

Next Coronavirus Market Crash: Where to Invest $1,000

SAN DIEGO--(BUSINESS WIRE)---- $TNDM #TNDM--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that John Sheridan, president and chief executive officer, will present a company update at the following virtual investor conferences: Wells Fargo 2020 Healthcare Conference on Wednesday, September 9, 2020 at 12:00pm Eastern Time (9:00am Pacific Time), Morgan Stanley 18th Annual Global Healthcare Conference on Wednesday, September 16, 2020 at 11:45a

Tandem Diabetes Care Announces Upcoming Webcast Conference Presentations

Per the DCLP5 study, Tandem Diabetes' (TNDM) insulin pump with Control-IQ technology suitable for use in children aged six to 13 years, which has been published in the NEJM.

Tandem Diabetes' Advanced Insulin Pump Study Results Favorable

SAN DIEGO--(BUSINESS WIRE)---- $TNDM #ControlIQ--Tandem announces New England Journal of Medicine publication of pediatric study showing increased time in range with Control-IQ technology.

Tandem Diabetes Care Announces NEJM Publication of Pediatric Study Demonstrating Increased Time-In-Range using the t:slim X2 Insulin Pump with Control-IQ Technology

DexCom

Novo Nordisk

DexCom, Tandem Diabetes, and Novo Nordisk have plenty of momentum and growth ahead, making them excellent buys this month.

3 Top Diabetes Stocks to Buy in August

Tandem Diabetes Care: Gaining Share In A Growing Market

Tandem Diabetes' (TNDM) strong domestic pump sales and pump shipments boosted the top line.

Tandem Diabetes (TNDM) Q2 Earnings & Revenues Top Estimates

Tandem Diabetes Care's (TNDM) CEO John Sheridan on Q2 2020 Results - Earnings Call Transcript

SAN DIEGO--(BUSINESS WIRE)---- $TNDM #ControlIQ--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2020.

Tandem Diabetes Care Announces Second Quarter 2020 Financial Results and Full Year 2020 Sales Guidance

SAN DIEGO--(BUSINESS WIRE)---- $TNDM--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Peyton Howell as an independent member of its board of directors effective August 3, 2020.

Tandem Diabetes Care Appoints Peyton Howell to Board of Directors

DaVita

Intuitive Surgical

Medtronic

Owens & Minor

1Life Healthcare

Walgreens

With so much focus and attention geared toward the novel coronavirus and the COVID-19 pandemic, health care has been affected in many strange ways.

7 Post-Coronavirus Health Care Stocks That Will Win in the Years Ahead

DUBLIN & SAN DIEGO--(BUSINESS WIRE)--Medtronic plc (NYSE:MDT) and Tandem Diabetes Care, Inc. (NASDAQ:TNDM) today announced that they have entered into a non-exclusive patent cross-license agreement for certain technologies in the field of diabetes. Cross-licensing each other’s patent portfolios enables both companies to focus on helping people with diabetes through innovation of future products and services, while avoiding the distraction of potential legal disagreements. With certain exclusion

Medtronic and Tandem Diabetes Care Enter Into Patent Cross-License Agreement

Two leaders in the diabetes market are teaming up to provide a better way to administer insulin to patients.

Abbott Deal, UnitedHealth Coverage Push Up Tandem Shares

Tandem Diabetes Care sees its Relative Strength Rating reach the elite 90-plus level.
The post Tandem Diabetes Care Shows Market Leadership With Jump To 94 RS Rating appeared first on Investor's Business Daily.

Tandem Diabetes Care Shows Market Leadership With Jump To 94 RS Rating

Abbott's (ABT) FreeStyle Libre CGM technology to be integrated with Tandem Diabetes' insulin pumps to enhance diabetes care.

Abbott, Tandem Diabetes Seal Deal on Diabetes Management

Tandem Diabetes (TNDM) expands digital portfolio with the Sugarmate app buyout, paving the way for the company's expansion of diabetes-related products and services ecosystem.

Tandem Diabetes' Sugarmate Buyout Boosts Digital Offerings

Which of these two diabetes partners is more likely to be the bigger winner over the long run?

Better Buy: DexCom vs. Tandem Diabetes Care

Tandem Diabetes (TNDM) receives clearance for expanded indication for pediatric use of t:slim X2 insulin pump with Control-IQ, paving the way for simpler diabetes management in younger patient pool.

Tandem Diabetes Gets Expanded Indication for Insulin Pump

Tandem Diabetes (TNDM) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Tandem Diabetes (TNDM) Looks Good: Stock Adds 6.5% in Session

Amid the widespread pandemic crisis, the diabetes management sector continues to thrive on account of multiple positive developments

3 Diabetes Management Stocks in the Spotlight Amid Coronavirus

Strong domestic pump sales and international expansion boosts sales of Tandem Diabetes (TNDM).

News for Tandem Diabetes Care Stock (TNDM)